199,000 mass tort cases are pending in the federal system as of Q1 2026.

Zero of them are a good deal for every PI firm.

That's the mistake. Mass tort marketing sells itself as universally lucrative — "sign cases, get paid, let the MDL do its thing." The economics are more complicated than that. For some firms, chasing the wrong tort at the wrong phase will incinerate capital faster than a string of denials.

Three mass torts are especially hot right now and each represents a different bet. Here's how to read them.

The three torts on the board

Nitrous oxide. Rapidly expanding. Plaintiffs allege manufacturers and distributors knowingly marketed nitrous cartridges in formats that encouraged recreational inhalation while downplaying brain-injury risks. Early phase — no bellwether yet, no settlement framework. Intake cost: low relative to sign rates. Time to payout: long, highly uncertain.

Social media addiction. First bellwether trial expected summer 2026. Claims against Meta, TikTok, Snap on product-liability theories for minor-user harms. Moderate intake cost (screening for actual harm is non-trivial). Bellwether outcome will reset the valuation of every pending case on the docket overnight.

Camp Lejeune. First bench-trial verdicts expected in 2026. These set the valuation benchmark for the entire 100K+ docket. Intake is closed-ish (the registration window was narrow) but firms with existing books are about to see every case re-anchored to whatever the first bench verdicts come back at. Firms without Camp Lejeune cases can't get in; firms with them are about to find out if they're sitting on a goldmine or a lukewarm book.

The three-dimensional read

Every mass tort has three variables that determine whether it's a good bet for your firm specifically.

Intake cost per signed case. How much marketing, screening, and medical work goes into saying yes. Early torts with loose screening look cheap but rack up costs on bad sign rates.

Time to payout distribution. Mean time from intake to payment. A 5-year wait for $30K average payout is different math than an 18-month wait for $22K.

Bellwether proximity and risk. Every mass tort has a gravity event — the first bellwether verdict or the first MSA — that either validates the book or craters it. Signing cases well before that gravity event is a different business than signing cases 60 days after.

Running those three variables over the three live torts:

  • Nitrous is a high-risk capital bet. Cheap intake now, huge upside if it goes MDL, real possibility of "interesting idea, nothing happens." Good fit for firms with slack capital and appetite for swing.
  • Social media addiction is a pre-bellwether positioning bet. Expensive to work up properly. The value of signing cases right now depends entirely on whether summer bellwethers come back favorably. Not a good fit for firms with tight cash flow.
  • Camp Lejeune is a book revaluation event, not a new intake play. If you don't have a book, you're not in the game. If you do, prepare for the bench-trial verdicts, don't chase more signups.

What AI actually changes here

Mass tort economics used to reward scale. One big intake funnel, volume marketing, assembly-line screening. That's why the top 5 mass tort firms did the bulk of the business.

AI makes the second and third tier firms competitive on the variable that matters most: intake quality.

Specifically:

  • AI-assisted medical screening means a mid-size firm can evaluate real-vs-weak injury claims at volume without building a 30-person medical-review department.
  • Pattern matching across past torts means firms can see early which torts are shaping up like Roundup vs. which look like they'll fade to nothing.
  • Case-value modeling means the sign/no-sign call is informed by comparable case outcomes in the MDL, in real time.

Firms that used to lose mass tort economics because they couldn't match the volume of the top 5 can now match them on unit economics. The big firms still win on scale. Mid-size firms win when they pick the right tort at the right time — which is exactly what AI analytics make possible.

The decision framework

Before you commit to any emerging mass tort, ask:

  1. Is the tort past its gravity event? If no, what's the timeline and the risk-adjusted payoff?
  2. What does your firm have that makes this specific tort yours? Local knowledge, existing client base, medical relationships — or nothing, in which case you're competing on marketing spend with firms that have deeper pockets.
  3. What does AI buy you in screening? If the answer is "nothing specific," skip it.
  4. What's the opportunity cost? Mass-tort capital deployed here is capital not deployed in local PI practice.

Most mid-size PI firms should only be in one or two mass torts at a time, carefully chosen. The firms that try to chase every wave end up with a docket full of files they can't work and a marketing bill that eats their local practice margin.

Where PIMP goes next

The next Field Manual entry walks through the actual math of a nitrous-oxide case book vs. a Missouri MVA book side by side — intake cost, time-to-payout, risk distributions, capital consumption. If you want the spreadsheet template we use for those comparisons, subscribe to the Field Manual.

If you want help thinking through whether your firm should be in any of these torts, book a recon call. We're running free mass-tort-portfolio reviews for PI firms this quarter. Thirty minutes, honest read, no pressure.

Stack wins.